SCHEMBL423290

SCHEMBL423290

CC1Cc2cc[c]cc2OO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17495240 0.81 TDP1 (0.40)
SCHEMBL11381215 0.73 MAOA (0.37)
Ammonia Solution, Strong SCHEMBL27661256 0.72 MAOA (0.35)
SCHEMBL17316655 0.71
SCHEMBL14167672 0.71
SCHEMBL1387744 0.70 TDP1 (0.47)
SCHEMBL5546848 0.68 CA1 (0.35)
SCHEMBL745905 0.67
SCHEMBL2879963 0.67
SCHEMBL5687860 0.65 BRD4 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1811991-B1 Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis GENZYME CORP (US) 2018-11-07 EP claimed
EP-1855696-B1 9A-CARBAMOYL-Y-AMINOPROPYL- AND 9A-THIOCARBAMOYL-Y-AMINOPROPYL-AZALIDES WITH ANTIMALARIAL ACTIVITY GLAXOSMITHKLINE ZAGREB (HR) 2010-04-28 EP claimed
US-20080200404-A1 Novel Antimalarial 9A-Carbamoyl-Aminoalkyl and 9A-Thiocarbamoyl-Aminoalkyl Azalides GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (HR) 2008-08-21 US claimed
EP-1855696-A2 9A-CARBAMOYL-Y-AMINOPROPYL- AND 9A-THIOCARBAMOYL-Y-AMINOPROPYL-AZALIDES WITH ANTIMALARIAL ACTIVITY GlaxoSmithKline istrazivacki centar Zagreb d.o.o. (HR) 2007-11-21 EP claimed
WO-2006085228-A2 9A-CARBAMOYL-Y-AMINOPROPYL AND 9A-THIOCARBAMOYL-Y-AMINOPROPYL-AZALIDES WITH ANTIMALARIAL ACTIVITY GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (GB) 2006-08-17 WO claimed
US-20060089503-A1 Processes for producing optically active 2-thiomethyl-3-phenylpropionic acid derivative and for producing intermediate therefor KANEKA CORPORATION (JP) 2006-04-27 US claimed
EP-1577310-A1 PROCESSES FOR PRODUCING OPTICALLY ACTIVE 2-THIOMETHYL-3-PHENYLPROPIONIC ACID DERIVATIVE AND FOR PRODUCING INTERMEDIATE THEREFOR KANEKA CORPORATION (JP) 2005-09-21 EP claimed
US-6403633-B2 USEFUL ANTIANGIOGENIC, ANTIARTHRITIC, ANTIINFLAMMATORY, ANTIRESTENOTIC, ANTIINVASIVE, ANTIMETASTIC, ANTIOSTEOPOROTIC, ANTIRETINOPATHIC, CONTRACEPTIVE AND TUMORISTATIC TREATMENT AGENTS 3-DIMENSIONAL PHARMACEUTICALS, INC. 2002-06-11 US claimed
US-6355634-B1 OXIME DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2002-03-12 US claimed
EP-1811991-B1 Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis GENZYME CORP (US) 2018-11-07 EP disclosed
EP-2923699-B1 METHODS OF TREATING FATTY LIVER DISEASE COMPRISING INHIBITING GLUCOSPHINGOLIPID SYNTHESIS GENZYME CORP (US) 2018-06-20 EP disclosed
US-20170281593-A1 Methods of Treating Fatty Liver Disease GENZYME CORPORATION 2017-10-05 US disclosed
US-9556155-B2 Methods of treating fatty liver disease GENZYME CORPORATION (US) 2017-01-31 US disclosed
US-9532976-B2 Method of lowering blood glucose GENZYME CORPORATION (US) 2017-01-03 US disclosed
WO-2000047578-A1 HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2000-08-17 WO disclosed
WO-1999040088-A1 HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 1999-08-12 WO disclosed
US-5726343-A REACTION OF A BORONIC ACID COMPOUND WITH A METHOXYIMINOACETIC ESTER, INSECTICIDES, MICROBIOCIDES NOVARTIS CORPORATION (US) 1998-03-10 US disclosed
US-5677322-A THERAPY FOR AGING, DIABETES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1997-10-14 US disclosed
EP-0638075-A1 THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1995-02-15 EP disclosed
WO-1994019335-A1 THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1994-09-01 WO disclosed